Title:
PHARMACEUTICAL COMPOSITION USED FOR TREATMENT OF HTLV-1-ASSOCIATED MYELOPATHY
Document Type and Number:
WIPO Patent Application WO/2018/135556
Kind Code:
A1
Abstract:
The present invention provides a pharmaceutical composition which can be used for the treatment of HTLV-1-associated myelopathy and contains an inhibitor selected from the group consisting of an EZH1 inhibitor, an EZH2 inhibitor and an EZH1/2 double inhibitor as an active ingredient. The present invention provides a pharmaceutical composition which can be used for the treatment of HTLV-1-associated myelopathy and contains a 1,3-benzodioxole derivative or a pharmaceutically acceptable salt thereof.
Inventors:
YAMANO YOSHIHISA (JP)
UEDA NATSUMI (JP)
ARAKI KAZUSHI (JP)
UEDA NATSUMI (JP)
ARAKI KAZUSHI (JP)
Application Number:
PCT/JP2018/001301
Publication Date:
July 26, 2018
Filing Date:
January 18, 2018
Export Citation:
Assignee:
DAIICHI SANKYO CO LTD (JP)
UNIV SCHOOL ST MARIANNA MEDICINE (JP)
UNIV SCHOOL ST MARIANNA MEDICINE (JP)
International Classes:
A61K45/00; A61K31/443; A61K31/496; A61K31/5377; A61P25/00; A61P43/00
Domestic Patent References:
| WO2015141616A1 | 2015-09-24 | |||
| WO2011129424A1 | 2011-10-20 | |||
| WO2015141616A1 | 2015-09-24 | |||
| WO2014100646A1 | 2014-06-26 | |||
| WO2015057859A1 | 2015-04-23 | |||
| WO2016081523A1 | 2016-05-26 | |||
| WO2014144747A1 | 2014-09-18 | |||
| WO2015010078A2 | 2015-01-22 | |||
| WO2015010049A1 | 2015-01-22 | |||
| WO2015200650A1 | 2015-12-30 | |||
| WO2015132765A1 | 2015-09-11 | |||
| WO2015004618A1 | 2015-01-15 | |||
| WO2016066697A1 | 2016-05-06 | |||
| WO2014124418A1 | 2014-08-14 | |||
| WO2015023915A1 | 2015-02-19 | |||
| WO2016130396A1 | 2016-08-18 | |||
| WO2015077193A1 | 2015-05-28 | |||
| WO2015077194A1 | 2015-05-28 | |||
| WO2015193768A1 | 2015-12-23 | |||
| WO2016073956A1 | 2016-05-12 | |||
| WO2016073903A1 | 2016-05-12 | |||
| WO2016102493A1 | 2016-06-30 | |||
| WO2016089804A1 | 2016-06-09 | |||
| WO2014151369A2 | 2014-09-25 | |||
| WO2011140324A1 | 2011-11-10 | |||
| WO2012142504A1 | 2012-10-18 |
Foreign References:
| JPS609135B2 | 1985-03-08 |
Other References:
MATSUZAKI, TOSHIO ET AL.: "Diagnosis and Progression of Treatment of HAM", JOURNAL OF MEDICAL TECHNOLOGY, vol. 49, no. 4, 2005, pages 409 - 414, XP8175747
YAMANO, YOSHIHISA: "HLTV-1-Associated Myelopathy (HAM): New Directions in Therapeutic Drug Development via Molecular Pathology Elucidation", JOURNAL OF CLINICAL AND EXPERIMENTAL MEDICINE (IGAKU NO AYUMI, vol. 255, no. 5, 31 October 2015 (2015-10-31), pages 485 - 490, XP009515799, ISSN: 0039-2359
YANG, X. ET AL.: "Structure-Activity Relationship Studies for Enhancer of Zeste Homologue 2 (EZH2) and Enhancer of Zeste Homologue 1 (EZH1) Inhibitors", JOURNAL OF MEDICINAL CHEMISTRY, vol. 59, no. 16, 11 August 2016 (2016-08-11), pages 7617 - 7633, XP055501542
STAZI, G. ET AL.: "EZH2 inhibitors: a patent review (2014-2016)", EXPERT OPINION ON THERAPEUTIC PATENTS, vol. 27, no. 7, April 2017 (2017-04-01), pages 797 - 813, XP055378039
ARAYA N. ET AL., VIRUSES, vol. 3, 2010, pages 1532 - 1548
OSAME M.: "Human Retrovirology: HTLV.", 1990, RAVEN PRESS, article "Review of WHO Kagoshima meeting and diagnostic guidelines for HAM/TSP", pages: 191 - 197
STAZI, G. ET AL., EXPERT OPINION ON THERAPEUTIC PATENTS, vol. 27, no. 7, 2017, pages 797 - 813
"GenBank", Database accession no. CAB02546.1
YAMANO ET AL., PLOS ONE, vol. 4, no. 8, 2009, pages e6517
CHEMICAL ABSTRACTS, Columbus, Ohio, US; abstract no. 1403254-99-8
YAMAUCHI ET AL., J INFECT DIS., vol. 211, no. 2, 2015, pages 238 - 48
YAMANO ET AL., BLOOD, vol. 99, no. 1, 2002, pages 88 - 94
See also references of EP 3572095A4
YAMANO, YOSHIHISA: "HLTV-1-Associated Myelopathy (HAM): New Directions in Therapeutic Drug Development via Molecular Pathology Elucidation", JOURNAL OF CLINICAL AND EXPERIMENTAL MEDICINE (IGAKU NO AYUMI, vol. 255, no. 5, 31 October 2015 (2015-10-31), pages 485 - 490, XP009515799, ISSN: 0039-2359
YANG, X. ET AL.: "Structure-Activity Relationship Studies for Enhancer of Zeste Homologue 2 (EZH2) and Enhancer of Zeste Homologue 1 (EZH1) Inhibitors", JOURNAL OF MEDICINAL CHEMISTRY, vol. 59, no. 16, 11 August 2016 (2016-08-11), pages 7617 - 7633, XP055501542
STAZI, G. ET AL.: "EZH2 inhibitors: a patent review (2014-2016)", EXPERT OPINION ON THERAPEUTIC PATENTS, vol. 27, no. 7, April 2017 (2017-04-01), pages 797 - 813, XP055378039
ARAYA N. ET AL., VIRUSES, vol. 3, 2010, pages 1532 - 1548
OSAME M.: "Human Retrovirology: HTLV.", 1990, RAVEN PRESS, article "Review of WHO Kagoshima meeting and diagnostic guidelines for HAM/TSP", pages: 191 - 197
STAZI, G. ET AL., EXPERT OPINION ON THERAPEUTIC PATENTS, vol. 27, no. 7, 2017, pages 797 - 813
"GenBank", Database accession no. CAB02546.1
YAMANO ET AL., PLOS ONE, vol. 4, no. 8, 2009, pages e6517
CHEMICAL ABSTRACTS, Columbus, Ohio, US; abstract no. 1403254-99-8
YAMAUCHI ET AL., J INFECT DIS., vol. 211, no. 2, 2015, pages 238 - 48
YAMANO ET AL., BLOOD, vol. 99, no. 1, 2002, pages 88 - 94
See also references of EP 3572095A4
Attorney, Agent or Firm:
OHNO Seiji et al. (JP)
Download PDF: